Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 15Ovarian Neoplasms 5Brain Neoplasms 4Neoplasms 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Advanced Breast Cancer 2Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-negative Metastatic Breast Cancer 1

Interventions

Cyclophosphamide 3Pyridoxine 2Amifostine 2trastuzumab deruxtecan 1sodium thiosulfate 1sargramostim 1sacituzumab govitecan 1eribulin 1Triptorelin Pamoate 1Trastuzumab 1Thiotepa 1Social Determinants of Health 1Radiotherapy 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Methotrexate 1Furosemide 1Etoposide 1Epoetin Alfa 1Duloxetine Hydrochloride 1Drug Therapy 1Doxorubicin 1Dihydrouracil Dehydrogenase (NADP) 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × eribulin × Breast × Clear all
NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡